HUTCHMED has announced the completion of patient enrollment in a Phase II trial for fanregratinib (HMPL-453), aimed at treating intrahepatic cholangiocarcinoma (IHCC) patients with FGFR2 fusion ...
Hutchmed Completes Enrollment in Phase II Trial of Fanregratinib in FGFR2-Altered Cholangiocarcinoma
NEW YORK – Hutchmed on Thursday said it has completed enrollment of a Phase II trial in China testing the FGFR1/2/3 inhibitor fanregratinib in patients with advanced intrahepatic cholangiocarcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback